★ Metabolic Longevity

Humanin

Metabolic Longevity · 10mg × 10 vials

Humanin tells stressed cells not to die, clears out damaged proteins, and dampens the growth-hormone axis in the way long-lived animals do naturally.

✓ 98%+ Purity ✓ Lab Tested ✓ COA on Request ✓ Discreet Shipping ✓ Direct Support
📋 Certificate of Analysis Request the third-party COA via Telegram
Quick Start
🧪
Format
Injectable (reconstituted) · 10mg × 10 vials
🎯
Who it's for
longevity stack add-on
💉
How it's run
0.5-1 mg SubQ per injection
When you'll notice
2-4 weeks metabolic/cognitive; subtle
Pricing
$325from · kit of 10
US: 2-5 day · Intl: 7-14 day
+ $40 ship · singles $20 · free over $1k per tier
10mg × 10 vials$325
Order / Consult on Telegram →
0 minutes (native); extended in HNG analog
Half-life
8-12 wk on / 4 wk off (or continuous low-dose)
Cycling
2-4 weeks metabolic/cognitive
First effects
metabolic-longevity
Class
Overview

What Is Humanin?

Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP) encoded inside the mitochondrial 16S rRNA gene, the same family as MOTS-c (encoded in the 12S rRNA). It was the founding member of the MDP family, discovered in 2001 by Hashimoto and characterized over the following two decades primarily by Pinchas Cohen's lab at USC Davis School of Gerontology. The defining trick is that mitochondria themselves encode and secrete Humanin as a stress-response signal, talking to the rest of the body when the cell is under metabolic or oxidative pressure. It's not a synthetic mimic of a host hormone, it's a hormone the mitochondria already make and decline production of with age.

Humanin works through four overlapping protective mechanisms. First, it directly binds and antagonizes pro-apoptotic proteins (BAX, tBID), preventing them from permeabilizing the mitochondrial membrane and triggering cell death. Second, it activates a trimeric receptor complex (CNTFR/WSX-1/gp130) that turns on JAK2/STAT3 survival signaling plus ERK1/2 and AKT pathways, the same axes that keep neurons resistant to amyloid-beta toxicity. Third, it binds IGFBP-3 and modulates the IGF-1 axis, decreasing circulating IGF-1 (which is part of the longevity story, since lower IGF-1 correlates with extended lifespan in model organisms). Fourth, it activates autophagy and the formyl peptide receptors FPRL1/FPRL2, the cellular cleanup machinery linked to healthspan. In plain language: Humanin tells stressed cells not to die, clears out damaged proteins, and dampens the growth-hormone axis in the way long-lived animals do naturally. The strongest preclinical evidence is in neuroprotection (Alzheimer's models, amyloid-beta toxicity) and metabolic health (beta-cell preservation, insulin sensitization). The synthetic HNG analog (S14G-Humanin) is roughly 1,000x more potent than native Humanin and is what most preclinical work uses; research-grade "Humanin" products on the market are typically native Humanin sequence, which is the lower-potency end of the spectrum.

Protocols

Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.

Protocol0.5-1 mg SubQ per injection
Frequency2-3x per week (e.g., Mon/Wed/Fri)
Duration8 weeks on, then 4 weeks off, reassess

10 mg vial + 1 ml BAC = 10 mg/ml, so 1 mg = 0.10 ml = 10 IU on a U-100 syringe. One HMN10 kit (10 vials) at 1 mg 2-3x/week = ~13-20 weeks of research, plenty for a full beginner block plus next cycle's start. First-timers usually won't feel anything dramatic in week 1-2. The signal is subtle, more like an ambient improvement in recovery, sleep depth, and cognitive clarity than a stimulant-style hit. If running for neuroprotection or longevity, the metabolic markers (fasting glucose, lipid panel, hsCRP) and the cognitive signal develop over 4-8 weeks.

Protocol1-2 mg SubQ per injection
Frequency3x per week
Duration8-12 week blocks, then 4 weeks off

2 mg 3x/wk = 6 mg/wk, which is the upper end of the typical community range (community reports cluster 0.5-2 mg per dose, 2-3x/wk). One HMN10 kit covers ~6-8 weeks at this band. This is the working dose for customers chasing the mitochondrial + neuroprotection signal as a real protocol, not just dabbling. Best stacked with MOTS-c (the other MDP) at this stage; the two peptides hit different mitochondrial pathways and compound.

Protocol2 mg SubQ per injection
Frequency3x per week (locked schedule, e.g., Mon/Wed/Fri morning)
Duration12 weeks on / 4 weeks off, can repeat 2-3 blocks per year

Advanced users almost always stack Humanin with MOTS-c (the canonical mitochondrial sibling stack) and often add SS-31 for the "mito trinity" (Humanin handles cytoprotection and the anti-apoptotic arm, MOTS-c handles AMPK and biogenesis, SS-31 handles cardiolipin stabilization and electron transport). Solo Humanin at advanced dosing is rare in the community. The HMN10 kit covers ~8 weeks at top dosing, so a full 12 week block needs ~1.5 kits, and most advanced users buy two HMN10 kits at the start of a cycle.

What To Expect
2-4 weeks metabolic/cognitive
noticeable change
subtle
noticeable change
not stimulant-like
noticeable change
Side Effects

Straight talk - what people actually report, and what the studies measured.

What users report
From forums, Discord & TikTok
  • Injection site irritation: mild, occasional - manageable with site rotation
  • Mild transient fatigue first 3-7 days: minority of users, settles by week 2
  • Mild headache: rare, usually at the higher (2 mg per dose) end
  • Dizziness in fasted states: reported by a small subset, usually when stacked with another AMPK activator or done on a long fast
  • Sleep changes: a small number of users report mild sleep disruption if dosed late in the day, which is why morning dosing is the community standard
  • No reports of cardiovascular, GI, or systemic toxicity signals at standard doses
  • - Divergence: Literature is essentially silent on human AEs (no RCT). Community treats Humanin as one of the cleanest peptides available, similar tolerability profile to MOTS-c and BPC-157. The gap between "no human safety data" and "users report nothing" is the same pattern as MOTS-c, and the same caveat applies: it's a research peptide, not a clinically tested drug, so absence of reports is not the same as proven safety.
  • Theoretical cancer concern: Because Humanin is anti-apoptotic (it prevents cells from dying), there is a theoretical concern that it could facilitate tumor growth in active cancers, particularly hormone-sensitive cancers (breast, prostate). No human data confirms this, but the mechanism is consistent enough that the conservative call is to avoid Humanin during active malignancy or recent cancer history.
What the studies show
Measured in clinical trials
  • No documented human RCT side effect rates. Humanin has not been tested in completed Phase 2 or Phase 3 human clinical trials as of May 2026. All human dosing data below comes from preclinical models, biohacker self-reports, and the broader peptide research community, not RCT.
  • Preclinical models (rodents, primarily mice) report Humanin as well-tolerated at therapeutic doses across multiple studies. No dose-limiting toxicities documented. The Reynolds 2018 Nature Sci Rep paper on cognitive decline used twice-weekly injections in middle-aged mice and reported improved cognitive scores without adverse signal.
The Research

Peer-reviewed studies and clinical guidelines - tap any to read the source.

PubMedHumanin Peptide Binds to IGFBP-3 and Regulates Its Interaction with Importin-beta, Ikonen et al

IGFBP3 binding mechanism, apoptosis suppression axis

Read study ↗
PubMedNeuroprotective Action of Humanin and Humanin Analogues, Tajima et al, MDPI Biology 2023

comprehensive review of neuroprotection mechanisms, HNG analog

Read study ↗
PubMedNeuroprotective Action of Humanin and Humanin Analogues, PMC10740898

same review, PMC entry

Read study ↗
PubMedThe mitochondrial-derived peptide humanin activates ERK1/2, AKT and STAT3 signaling pathways, Oncotarget 2016

signaling pathway mechanism in hippocampus

Read study ↗
PubMedThe emerging role of the mitochondrial-derived peptide humanin in stress resistance, Lee et al, J Mol Endo 2013

Cohen lab review on stress resistance

Read study ↗
PubMedHumanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans, Sci Rep 2018

twice-weekly HNG in middle-aged mice, cognitive improvement

Read study ↗
+ 10 more studies & references
From The Community

Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.

SSwolverine Humanin Beg

Injection site irritation: mild, occasional - manageable with site rotation

PPeptideDeck Humanin re

Mild transient fatigue first 3-7 days: minority of users, settles by week 2

TThe Peptide Catalog Hu

Mild headache: rare, usually at the higher (2 mg per dose) end

PPeptide Reference Huma

Dizziness in fasted states: reported by a small subset, usually when stacked with another AMPK activator or done on a long fast

PPeptIQ SS-31 + MOTS-c

Sleep changes: a small number of users report mild sleep disruption if dosed late in the day, which is why morning dosing is the community standard

PPeptide Insight Humani

No reports of cardiovascular, GI, or systemic toxicity signals at standard doses

Common Questions
SubQ. 0.5-1 mg SubQ per injection
2-4 weeks metabolic/cognitive; subtle, not stimulant-like
Yes - baseline labs before starting and a recheck a few weeks in is the standard advice. We can walk you through which markers to watch.
A popular pairing is Humanin + MOTS-c (the canonical mitochondrial sibling stack). See the Protocols section, or ask us for a stack built around your goal.
Yes. Every batch is third-party lab tested - request the COA on Telegram and we send it over.
Safety & Contraindications

Hard stops

  • Active malignancy or history of cancer within the last 5 years - Humanin's anti-apoptotic mechanism is the central concern; the prudent default is no
  • Active chemotherapy or radiation treatment
  • Pregnancy or breastfeeding (no data, default to no for any research peptide)
  • Active hormone-sensitive cancer (breast, prostate, ovarian)

Caution flags

  • Family history of hormone-sensitive cancers
  • Customers on insulin or sulfonylureas - Humanin has insulin-sensitizing effects, watch glucose closely the first 2-4 weeks
  • Type 1 diabetes without endocrinologist oversight
  • Severe mitochondrial disorders (genetic) - unclear interaction
  • Active autoimmune flares - JAK/STAT activation could theoretically influence inflammation patterns, no clinical data either way

Stacking conflicts

  • No documented direct conflicts. Humanin stacks cleanly with MOTS-c, SS-31, NAD+, BPC-157, TB-500, CJC+Ipa, GHK-Cu, 5-Amino-1MQ, GLOW/KLOW blends, melanotan, semax, selank, reta, tirz, sema, cagrilintide.
  • Theoretical caution with high-dose IGF-1 modulators (since Humanin lowers IGF-1, stacking with compounds that aggressively raise IGF-1 may blunt one side of the effect, not a safety issue)
Is It Right For You?

✓ Good fit

  • longevity stack add-on
  • mitochondrial health focus
  • neuroprotection / cognitive aging focus
  • Alzheimer's family history
  • 50+ healthspan customers
  • MOTS-c stackers wanting to deepen the mito protocol
  • long covid / chronic fatigue / Lyme recovery
  • post-GLP-1 maintenance for older customers
  • biohacker / Bryan Johnson archetype
  • mitochondrial trinity (Humanin + MOTS-c + SS-31) customers

✗ Not a fit

  • active cancer patients
  • recent cancer history
  • customers chasing rapid scale weight changes
  • customers wanting a stimulant-style energy hit
  • customers who haven't run a single peptide before (start with MOTS-c or BPC, layer Humanin later)
  • pregnancy / trying to conceive

Administration & Storage

Route: SubQ

Injection site: abdomen or outer thigh, rotate sites

Storage: refrigerated, ~28-30 days after reconstitution

Notes: Half-life of native Humanin is short (~30 min in plasma), so timing and frequency matter more than with long-acting peptides. Morning dosing is the community default, partly for circadian alignment with mitochondrial stress-response cycles and partly to avoid any sleep disruption. Swirl gently to mix, don't shake. Use a fresh insulin syringe per draw. The native peptide is also temperature-sensitive, so keep unreconstituted vials refrigerated and reach room temp before injecting once mixed.

All products sold for research purposes only. Not for human or animal consumption. Must be 21 or older to purchase. By placing an order you confirm compliance with all applicable local laws and regulations.